EOS imaging Announces First Bracing Facility Installation

Regulatory News :

EOS Imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging and associated solutions, today announced the installation of an EOS® imaging system at National Scoliosis Center, a Virginia-based scoliosis treatment clinic.

Until today, EOS installations have been installed solely in hospitals or imaging centers. The National Scoliosis Center’s installation is the first of its kind. National Scoliosis Center provides on-site custom design and fabrication of scoliosis and kyphosis braces and offers Schroth scoliosis specific physical therapy for patients in the course of non-operative treatment of scoliosis.

EOS® will provide real-time solutions for National Scoliosis Center’ adult and pediatric patients, who require frequent radiographs to monitor their curves and the effectiveness of treatment. Previously, patients would have imaging radiographs conducted in a hospital or outpatient center, before going to an orthotic company to be fitted for a brace.

With EOS®, National Scoliosis Center will be able to conduct radiographic imaging scans and create braces for patients all in one location. EOS® accurate 3D measurement, including the 3D reconstruction of the ribcage for advanced brace computer assisted design (CAD) will assist orthotists in designing and fabricating better braces to effectively treat each patient’s condition.

Additionally, scoliosis patients require regular imaging, during the initial design and delivery of the brace and over the course of care that frequently lasts many years. EOS® ultra-low dose imaging enables National Scoliosis Center to safely scan the patients as many times as necessary with limited radiation exposure.

"In our continuing efforts to provide quality patient care, we are excited to offer EOS® imaging to our clients. We frequently brace each scoliosis patient multiple times over his or her course of treatment. By housing imaging capabilities on-site, we will be able to assist our patients more effectively and efficiently while providing maximum safety by lowering imaging dose exposure thanks to EOS unique technology,” said Luke Stikeleather, CEO, founder of National Scoliosis Center.

Marie Meynadier, CEO of EOS imaging, said, "National Scoliosis Center is our first U.S. customer to take advantage of EOS® to develop a one-stop solution for bracing treatment of scoliosis patients. With the addition of EOS® to their offering, scoliosis patients and their families gain a convenient, comprehensive and de-risked approach to treatment. National Scoliosis Center is a pioneer in full-service bracing and we expect this trend to develop both in the U.S. and abroad.”

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D. EOS® exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans, as well as related software solutions. The new EOS® Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: revenue for the 1st half of 2015, on July 20, 2015 (after market).

About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled Georges Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and Singapore.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150707006217/en/